Story perspectives

AI Innovations Boost Drug Formulation Success by 43%

9/26/2025

Summary

Story summary

The TuNa-AI platform achieved a 43% increase in successful venetoclax formulations versus traditional methods.
Duke University launched TuNa-AI to design nanoparticles for drug delivery, using AI and automated lab work to improve formulation efficiency and safety.
University of Washington researchers developed an AI-engineered protein that deactivates interleukin-2, enabling precise immune control in cancer therapies and potentially improving safety.

History

Historical Context

The FDA's approval of ipilimumab in 2012 marked a pivotal moment in cancer treatment, introducing immunotherapy as a viable option. Duke University's TuNa-AI platform has since enhanced drug formulation success rates by 43%, reflecting the ongoing integration of AI in medical research. These advancements signify a transformative era in cancer therapies, promising improved patient outcomes and safety.

1 of 2

Story summary

The TuNa-AI platform achieved a 43% increase in successful venetoclax formulations versus traditional methods.
Duke University launched TuNa-AI to design nanoparticles for drug delivery, using AI and automated lab work to improve formulation efficiency and safety.
University of Washington researchers developed an AI-engineered protein that deactivates interleukin-2, enabling precise immune control in cancer therapies and potentially improving safety.

1 / 2